Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration

Current Opinion in Cell Biology

Volumn 9, Issue 5, 1997, Pages 714-724

  Chapman, Harold A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; INTEGRIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

CELL ADHESION; CELL MIGRATION; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 0030842795     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(97)80126-3     Document Type: Article

References (67)

1. Reich E: Activation of plasminogen: a widespread mechanism for generating localized extracellular proteolysis. In Biological Markers of Neoplasia: Basic and Applied Aspects. Edited by Ruddon EW. New York: Elsevier; 1978:491-500.
2. Blasi F, Vassalli JD, Dano K: Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987, 104:801-804.
3. Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D: Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988, 263:15454-15461.
4. Podor TJ, Joshua P, Butcher M, Seiffert D, Loskutoff D, Gauldie J: Accumulation of type 1 plasminogen activator inhibitor and vitronectin at sites of cellular necrosis and inflammation. Ann NY Acad Sci 1992, 667:173-177.
5. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K: Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991, 266:1926-1933.
6. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990, 9:1079-1085.
7. Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen El, Blasi F: alpha-2 macroglobulin receptor/Ldl receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 1995, 131:1609-1633.
8. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF: Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1996, 385:537-540. This study examines the quantitative effects of matrix ligand concentration, integrin expression, and integrin activation (by expression of an 'activated' conformation) on the speed of cellular movement in vitro. The authors convincingly show that migration depends on an optimal level of adhesiveness whether achieved by relatively low matrix ligand concentration and high integrin binding or high ligand concentration and low integrin avidity. These results imply that the effects of manipulation of integrin function on cellular migration depend critically on the matrix environment in which the integrins are functioning.
9. Nusrat AR, Chapman HA: An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991, 87:1091-1097.
10. Gyetko MR, Todd RF III, Wilkinson CC, Sitrin RG: The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994, 93:1380-1387.
11. •].
12. •] look at interesting recent examples of a growing superfamily of metalloproteases that also contain noncatalytic protein domains that directly influence integrin function and cellular signalling. These transmembrane proteases share with urokinase-uPAR complexes the capacity to intrinsically link proteolysis and cellular adhesion.
13. Brooks PC, Stromblad S, Sanders LC, von Schalascha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996, 85:683-694. This report is the first to demonstrate a functionally important membrane-binding site for matrix metalloprotease (MMP)-2 and raises the possibility that other MMPs could also be membrane-associated. This provides a mechanism by which metalloproteases without a transmembrane domain or disintegrin activity could be linked to the adhesive machinery of cells.
14. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter SS, Degen JL: Resolution of spontaneous bleeding but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995, 9:2020-2033.
15. Bugge TH, Flick MJ, Daugherty CC, Degen JL: Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995, 9:794-807.
16. ••].
17. ••] probably heralds the elucidation of much new information from the cross-breeding of mice with various selective deficiencies in proteases and from study of the resulting mice in models of tissue injury and tumor progression.
18. Carmeliet P, Schoojans L, Kieckens L, Ream B, Degen J, Bronson R, DeVos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424.
19. Carmeliet P, Stassen L, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D: Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1994, 92:2756-2760.
20. ••].
21. ••] is that extravascular fibrin deposition in the context of acute and/or chronic lung injury is an important contributor to the pathobiology and not simply a marker for the process. These are the first studies to directly demonstrate this point in an in vivo context.
22. Chapman HA, Bertozzi P, Reilly JJ Jr: Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest 1988, 93:1256-1264.
23. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romer J, Solberg H, Ellis V, Dano K: The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995, 270:16886-16894.
24. •].
25. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JI: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996, 93:5899-5904.
26. Pedersen TL, Yong K, Pedersen JO, Hansen NE, Dano K, Plesner T: Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1996, 95:45-51.
27. Behrendt N, Ronne E, Dano K: Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996, 271:22885-22894.
28. Gudewicz PW, Gilboa N: Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun 1987, 147:1176-1181.
29. Fibbi G, Ziche M, Morbidelli L, Magnelli L, Del Rosso M: Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 1988, 179:385-395.
30. Rao N, Shi GP, Chapman HA: Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 1995, 96:465-474.
31. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect EMBO J 1996, 15:1572-1582. This nice study directly demonstrates the occurrence of signalling as a consequence of urokinase receptor (uPAR) occupancy by urokinase, and shows that a soluble version of uPAR itself can associate with cells and transmit similar signals, implying that cells express a 'partner' for uPAR that couples the receptor to the signalling machinery of cells.
32. •].
33. •] strongly suggests an in vivo role for urokinase in addition to its role as an initiator of fibrinolysis. It remains to be defined whether the demonstrated defects in host defense are explained by the lack of urokinase proteolytic activity (such activity might be important in cytokine or metalloprotease activation) or whether they are more related to defective cell signalling and integrin function.
34. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994, 269:32380-32388.
35. •].
36. •] argue that the somatomedin B domain of vitronectin contains the uPAR-binding site. This is consistent with the localization of the known high affinity binding site for PAI-1 within the somatomedin B domain.
37. Waltz DA, Natkin LR, Fijita RM, Wei Y, Chapman HA: Interaction of urokinase receptors with vitronectin: regulation by plasminogen activator inhibitor type 1 and plasmin. J Clin Invest 1997, 100:58-67.
38. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990, 111:783-792.
39. Vaheri A, Stephens RW, Salonen EM, Pollanen J, Tapiovaara H: Plasminogen activation at the cell surface-matrix interface. Cell Differentiation Dev 1990, 32:255-262.
40. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Ulrich WH, Otto M, Bartke I, Knapp W, Stockinger H: Urokinase plasminogen activator receptor, β2-integrins, and src-kinases within a single receptor complex of human monocytes. J Exp Med 1995, 181:1381-1390.
41. Kindzelskii AL, Laska ZO, Todd RF III, Petty HR: Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M/beta 2 CD11b/CD18) during neutrophil polarization. J Immunol 1996, 156:297-309. The authors of this paper used both immunofluoresence and resonance energy transfer methodologies to show that interactions between the urokinase receptor and β2 integrins are dynamically regulated by changes in cell shape.
42. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA: Regulation of integrin function by the urokinase receptor. Science 1996, 273:1551-1555. Demonstrates that the urokinase receptor forms functionally relevant tripartite complexes with caveolin, a major protein of the membrane structures caveolae, and integrins, membrane receptors not currently thought of as being connected to caveolae. The formation of these complexes probably alters the capacity of both caveolin and integrins to mediate intracellular signalling.
43. Sitrin RG, Todd RF III, Petty HR, Brock TG, Shollenberger SB, Albrecht E, Gyetko MR: The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996, 97:1942-1951.
44. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA: Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996, 88:3185-3194.
45. Stahl A, Mueller BM: The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995, 129:335-344.
46. Li S, Couet J, Lisanti MP: Src tyrosine kinases, G alpha subunits, and H-ras share a common membrane-anchored scaffolding protein, caveolin. J Biol Chem 1996, 271:29182-29190. Demonstrates that a membrane-proximal region of caveolin has the capacity to bind multiple, distinct signalling molecules. This paper and prior work from this group establish that caveolin is an organizing agent in the membrane for regulating signalling pathways.
47. Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG: The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell 1996, 87:733-743. These investigators observed that the membrane protein caveolin is a possible linker between certain β1 integrins and Shc. In these studies, Shc mediated downstream signalling through ras to regulate cell cycle progression. It is interesting that the cell line used for much of this work, A431 cells, expresses large amounts the urokinase receptor.
48. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L: Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994, 126:259-270.
49. Xue W, Mizukami I, Todd RF III, Petty HR: Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997, 57:1682-1689.
50. 5-directed cell migration. J Biol Chem 1996, 271:29392-29399.
51. Bauer JS, Schreiner CL, Giancotti FG, Ruoslahti E, Juliano RL: Mobility of fibronectin receptor-deficient cells on fibronectin and vitronectin: collaborative interactions among integrins. J Cell Biol 1992, 116:477-487.
52. Stahl A, Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997, 71:116-122.
53. Bianchi E, Ferrero E, Fazioli F, Mangili F, Wang J, Bender JR, Blasi F, Pardi R: Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest 1996, 98:1133-1141. This study reports the interesting observation that ligation of both T cell receptors and integrin receptors, but not of either receptor alone, results in robust upregulation of the urokinase receptor (uPAR) in a matter of hours. Ligation of either β1 (VLA4) or β2 (LFA-1) integrins was effective. The authors propose that uPAR upregulation facilitates migration of stimulated T cells through extravascular matrices.
54. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D: Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem 1996, 61:430-443.
55. Irigoyen JP, Besser D, Nagamine Y: Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem 1997, 272:1904-1909.
56. Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K: Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J 1991, 10:3399-3407.
57. •].
58. •] demonstrates that plasminogen activator inhibitor-1 directly impairs the interaction between integrin vitronectin receptors (αvß3 and αvβ5) and vitronectin. This inhibited the capacity of cells bearing these integrins to migrate in vitro on or toward vitronectin.
59. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993, 24:195-208.
60. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993, 53:2513-2521.
61. Hofmann R, Lehmer A, Buresh M, Hartung R, Ulm K: Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996, 78:487-492. This study is an interesting recent example of accumulating evidence that tumor levels of plasminogen activator inhibitor-1 are an independent prognosticator of tumor progression for many epithelial tumors.
62. Dvorak HF: Tumors: wounds that do not heal. New Engl J Med 1986, 315:1650-1659.
63. Hajjar KA, Jacovina AT, Chacko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994, 269:21191-21197.
64. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J: Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993, 82:2414-2422.
65. Nykjaer A, Conese M, Christensen El, Olson D, Cremona O, Gliemann Blasi F: Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997, 16:2610-2620.
66. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan HC: Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995, 96:2593-2600.
67. Eitzman DT, Krauss JC, Shen TL, Cui JS, Ginsburg D: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996, 11:4718-4722.